

ARDEA - Entering the Pivotal Phase

<https://marketpublishers.com/r/A800D152D2AEN.html>

Date: September 2011

Pages: 3

Price: US\$ 140.00 (Single User License)

ID: A800D152D2AEN

Abstracts

After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII development plans for Lesinurad (RDEA594, Urate Transporter regulator, Gout, PhIII) and expects to initiate the trials by 4Q11. There is a major unmet medical need for a better treatment option for the majority of gout pts. How will Lesinurad target the WW gout market? Management plans on the development/partnering etc. of Lesinurad is discussed in the report released on 12th September, 2011 on RDEA titled "Entering the Pivotal Phase". For more details please ask for our initiation report on Ardea.

Contents

COMPANIES MENTIONED

ARDEA

I would like to order

Product name: ARDEA - Entering the Pivotal Phase

Product link: <https://marketpublishers.com/r/A800D152D2AEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A800D152D2AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970